Finally, we performed gene expression analysis of these three immune checkpoint genes in low-risk and high-risk groups of BLCA and showed significant differences in the expression of SIGLEC15 (Figure 10D, p = 0.00036), HAVCR2 (Figure 10E, p = 0.0021), and PDCD1LG2 (Figure 10F, p = 0.00019) genes. This evidence concerns the gene SIGLEC15 and bladder transitional cell carcinoma.